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Gestational diabetes mellitus (GDM), defined as glucose intolerance 
with onset or first recognition during pregnancy,[1] is one of the 
leading causes of morbidity and mortality for mothers and infants 
worldwide. Globally, ~16.2% (21.3 million) of live births are associated 
with hyperglycaemia in pregnancy, of which 86.4% are due to GDM, 
6.2% to pre-existing type 1 diabetes (T1D) or type 2 diabetes (T2D), 
and 7.4% to T1D and T2D first detected during pregnancy.[2] The 
prevalence of GDM is rapidly increasing worldwide, possibly owing 
to advanced child-bearing age and obesity. This is particularly 
concerning, as South African (SA) women are considered among 
the most overweight globally.[3] GDM is associated with maternal 
(pre-eclampsia, increase in caesarean deliveries, birth trauma), 
fetal (macrosomia, hypoglycaemia, shoulder dystocia) and perinatal 
(respiratory distress syndrome, jaundice, metabolic derangements) 
complications, while mothers and their offspring are at risk of 
developing obesity, T2D and other metabolic conditions later in life. 
GDM thus poses a threat to maternal and child well-being, while 
its impact on the burden of non-communicable diseases (NCDs) 
is undeniable. This review provides an update of GDM in SA, 
focusing on risk factors and prevalence. Furthermore, we highlight 
recommendations for future research. 
Risk factors for gestational diabetes 
mellitus
The exact mechanism underlying GDM is not yet fully elucidated, 
although it is speculated that women who develop GDM may have 
underlying insulin resistance and genetic susceptibility.[4] GDM 
is reported to affect ~14% of pregnancies globally; however, rates 
between 1% and 28% are reported in different regions and vary 
according to ethnicity,[5] geographical location (urban v. rural),[6] 
environmental factors and screening and diagnostic strategies 
employed.[7] In the USA, for example, the prevalence of GDM was 
reported to be 11.1% in Asian Indians and 4.1% in non-Hispanic 
whites,[5] while in Tanzania, the prevalence of GDM was 1% and 8.4% 
in a rural and urban setting, respectively.[6] Although data are scant, 
the prevalence of GDM in SA is estimated to be 1.6 - 25.8%, based on 
various screening and diagnostic strategies employed.[8,9] 
Other definable risk factors that affect GDM prevalence include 
advanced maternal age, overweight and obesity, family history of 
diabetes, previous history of GDM and previous adverse pregnancy 
outcomes (Table 1).[10] Alarmingly, the rate of obesity is increasing 
dramatically, with SA now regarded as one of the world’s most obese 
nations.[11] According to recent statistics, ~69% of SA women are 
overweight or obese.[3] The increasing risk of obesity is largely due 
to changes in lifestyle, which have contributed to the increasing 
prevalence of T2D and metabolic syndrome, particularly among 
females.[11] Although universal screening, whereby all pregnant 
women undergo the diagnostic 75 g oral glucose tolerance test 
(OGTT) at 24 - 28 weeks of gestation, has been widely advocated as 
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Table 1. Risk factors for gestational diabetes mellitus
Advanced maternal age (≥35 years)
Overweight and obesity (BMI ≥25 kg/m2 or ≥30 kg/m2)*
Family history of diabetes mellitus
Previous history of gestational diabetes mellitus
High-risk ethnic groups (Hispanic, African, native American, 
Asian, Pacific islander, indigenous Australian)
Previous adverse pregnancy outcomes (e.g. recurrent miscarriages, 
congenital abnormalities, stillbirths, macrosomia)
BMI = body mass index.
*BMI cut-offs vary according to ethnicity.[5]
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the recommended screening strategy for GDM,[12] selective screening 
based on risk factors is now predominantly used in SA, as it is 
considered less costly than subjecting all women to laboratory testing. 
However, risk factor-based selective screening has been found to have 
poor sensitivity and specificity in many studies,[13,14] including our 
study,[9] and performs poorly as a screening tool for GDM. Moreover, 
selective screening places a high demand on healthcare workers to 
identify patients who should be screened and is often poorly adhered 
to, leading to inadequate screening and testing of GDM.
HIV and gestational diabetes mellitus
SA has the highest burden of HIV globally, with 7.1 million people 
living with the virus,[15] and ~19% of adults (15 - 49 years of age) 
affected by the disease.[16] HIV infection and antiretroviral therapy 
dysregulate glucose metabolism and are associated with an increased 
risk of glucose intolerance and metabolic disease.[17-19] There is 
evidence that antiretroviral therapy, particularly first-generation 
protease inhibitors, induces insulin resistance in both pregnant and 
non-pregnant women.[20] The risk of developing GDM is shown 
to be more common in HIV-infected women receiving combined 
antiretroviral therapy, especially with protease inhibitors.[21,22] 
Although protease inhibitors have been replaced by non-nucleoside 
reverse transcriptase inhibitors, which are considered safer, they too 
affect glucose homeostasis,[23] thus requiring further investigation. 
Current data in SA show no association between HIV infection and 
antiretroviral therapy and GDM.[9]
Complications of gestational diabetes 
mellitus
GDM is associated with adverse short- and long-term pregnancy 
outcomes in mothers and their offspring (Table 2). A study of 
57 629 women with GDM reported that the prevalence of caesarean 
delivery, macrosomia, preterm birth and pre-eclampsia was 27.8%, 
15.7%, 8.4% and 2.6%, respectively.[24] Fetal macrosomia is a common 
adverse obstetric outcome, affecting ~15 - 45% of neonates born 
to women with GDM, and is associated with an increased risk 
of caesarean delivery, shoulder dystocia, birth injury, respiratory 
distress syndrome and neonatal hypoglycaemia.[25,26] Furthermore, 
~50% of women with GDM will develop T2D within 10 years,[27] 
while evidence increasingly shows that women with GDM have a 56% 
higher risk of developing cardiovascular disease[28] and an increasing 
risk of metabolic syndrome later in life.[29] GDM is associated with 
an abnormal intrauterine environment that negatively affects the 
long-term health of offspring, possibly through epigenetic changes. 
It is estimated that children born to mothers with GDM have an 
8-fold increased risk of developing T2D and prediabetes compared 
with children born to mothers with normoglycaemic pregnancies.[30] 
Treatment of GDM improves outcome; therefore, early detection 
and appropriate management are critical to prevent pregnancy 
complications. However, a challenge that hampers the early detection 
and management of GDM is the current lack of global consensus 
on GDM screening and diagnosis, which varies between countries 
and institutions. A recent study conducted by Meek et al.[31] found 
that women who were diagnosed with GDM according to the 
stringent International Association of Diabetes in Pregnancy Study 
Groups (IADPSG) criteria, but were missed when using the National 
Institute for Health and Care Excellence (NICE) criteria, had a 
substantial risk of obstetric complications, such as macrosomia, 
caesarean section and polyhydramnios.
Prevalence of gestational diabetes 
mellitus in South Africa
SA is undergoing an epidemiological transition characterised by an 
increase in NCDs due to urbanisation, nutritional transition towards 
a diet consisting of high fat and refined sugars and sociocultural 
factors involving perception of overweight as a measure of success 
and beauty. Approximately 69% of SA women are overweight, 40% 
are obese and 20% are morbidly obese,[3,32] and are considered 
among the most overweight women globally, particularly those of 
reproductive age. Accordingly, GDM has rapidly increased in SA, 
with the prevalence ranging from 1.6% to 25.8% between 1969 and 
2018 (Table 3). The first GDM prevalence study was conducted in 
1969 among Indian women from KwaZulu-Natal Province using 
the 100 g OGTT. A prevalence of 23.8% and 8.3% was reported in 
women with and without risk factors, respectively.[33] In 1979, using 
risk-factor screening and the 50 g OGTT, a GDM prevalence of 3% 
was reported in women of mixed ethnic ancestry in Western Cape 
Province.[34] Using the World Health Organization (WHO) 1985 
diagnostic criteria, Ranchod et al.,[8] in KwaZulu-Natal, reported 
a GDM prevalence of 1.6% and 3.8% in women of Indian and 
Table 2. Adverse outcomes associated with gestational diabetes mellitus
Mother Offspring
Short-term Spontaneous miscarriage Structural malformations (e.g. brain, heart)
Pre-eclampsia/pregnancy-induced hypertension Macrosomia
Infections (e.g. urinary tract, puerperal sepsis) Shoulder dystocia – birth trauma
Caesarean delivery Premature birth – metabolic complications (hypoglycaemia, 
hypocalcaemia)
Labour complications, including instrumental 
deliveries and birth trauma
Polycythaemia/jaundice
Preterm delivery Respiratory distress syndrome
Polyhydramnios Cardiomyopathy/arrhythmias
Postpartum haemorrhage Stillbirth
Long-term Weight gain/obesity Obesity
Gestational diabetes mellitus in subsequent 
pregnancies
Type 1 diabetes 
Type 2 diabetes Type 2 diabetes
Cardiovascular disease Metabolic syndrome
Metabolic syndrome
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mixed ethnic ancestry, respectively.[8] A population-based study 
conducted in rural Limpopo Province reported a GDM prevalence 
of 8.8% in black women, using the WHO 1999 diagnostic criteria,[35] 
while a study of overweight and obese pregnant women of mixed 
ethnic ancestry in Johannesburg, Gauteng Province, showed a 
GDM prevalence of 1.8% using random and fasting glucose 
concentrations.[36] More recently, using the IADPSG criteria, a high 
prevalence of GDM (25.8%) was reported in black women from 
Johannesburg.[9] To date, the largest GDM prevalence study in SA 
found a prevalence of 9.1% in black women from Johannesburg, 
using the revised WHO 2013 diagnostic criteria, which are similar 
to the IADPSG criteria.[37] 
Disparities in the prevalence of GDM were observed between 
the abovementioned studies, which may be due to the different 
screening and diagnostic criteria. More recent studies, using 
the less stringent IADPSG[9] or WHO 2013[37] criteria, show an 
increased prevalence of GDM compared with older criteria, which 
used higher glucose thresholds.[8,33-36] Thus, although the increased 
prevalence of GDM may partly be due to diagnostic criteria, the 
role of the increasing obesogenic environment in SA should not 
be underestimated.[3] Other factors, such as geographical setting, 
maternal age and population and environmental differences, could 
also account for the disparities in prevalence across studies.[9,35,37]
Treatment
Management and treatment of GDM are important to reduce adverse 
pregnancy outcomes and improve maternal and neonatal health.[39] In 
SA, pregnant women with GDM are referred to the nearest secondary 
or tertiary hospital for management and treatment.[40] At the tertiary 
level, management of GDM is through counselling and health 
education provided by obstetricians, endocrinologists, dieticians or 
nurse educators. The primary form of intervention for women with 
GDM is lifestyle modification, which involves counselling regarding 
diet and physical activity. A dietary meal plan is provided, which 
entails reduced sugar and starch intake, increased protein intake 
and reduced total calorie intake.[40] However, in disadvantaged 
settings, these lifestyle changes are difficult to adhere to owing to 
the high cost of healthy food and lack of understanding and social 
support. A more sustainable approach is to counsel patients on how 
to reduce the glycaemic index of staple foods. The glycaemic index 
of carbohydrate-rich foods (e.g. potatoes, pap, pasta, rice) can be 
reduced by cooking, cooling and reheating, or by adding fats or acids 
such as lemon juice or vinegar.[41] 
Pharmacological therapy is initiated for women who fail to reach 
their glucose targets using diet and exercise. In SA, metformin is 
the drug of choice to treat GDM, while glyburide is used when 
metformin and insulin are not available. Although insulin is invasive 
and used only if metformin fails, it is effective, allows tight glucose 
control and is considered safe, as it does not cross the placenta. 
Generally, oral agents are preferred to insulin because of ease of 
administration, although studies conducted in other settings showed 
no substantial differences in major outcomes when comparing their 
benefits and risks.[42,43] 
Current perspectives and future 
recommendations
• The rate of obesity is rising dramatically, thus increasing the 
prevalence of GDM globally and in SA.
• Untreated GDM negatively affects maternal and child health.
• GDM increases the risk of developing T2D and other NCDs later 
in life.
• Future research should focus on reducing obesity and preventing 
the development of GDM.
Conclusions 
The prevalence of GDM is rapidly increasing in SA and is becoming 
a major public health concern. Without appropriate glucose 
management, GDM is associated with adverse pregnancy outcomes 
and an increased risk of future metabolic conditions in mothers and 
their offspring, further contributing to the growing burden of NCDs. 
Although the significant increase in the prevalence of GDM observed 
in recent SA studies may be attributed to the lower diagnostic 
thresholds used, the role of the increasing obesogenic environment 
should not be underestimated. Future research should focus on 
reducing the rising obesity epidemic and in so doing aim to prevent 
the development of GDM. Such initiatives will have a positive impact 
on decreasing maternal and child morbidity and mortality and the 
future burden of NCDs. 
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